Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Gains from Investment Securities: 2018-2025

Historic Gains from Investment Securities for Autolus Therapeutics (AUTL) over the last 2 years, with Sep 2025 value amounting to $501,000.

  • Autolus Therapeutics' Gains from Investment Securities fell 23.63% to $501,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 93.37%. This contributed to the annual value of $2.4 million for FY2024, which is 94.19% down from last year.
  • Latest data reveals that Autolus Therapeutics reported Gains from Investment Securities of $501,000 as of Q3 2025, which was down 48.19% from $967,000 recorded in Q2 2025.
  • Autolus Therapeutics' 5-year Gains from Investment Securities high stood at $28.5 million for Q3 2021, and its period low was -$29.2 million during Q4 2021.
  • In the last 3 years, Autolus Therapeutics' Gains from Investment Securities had a median value of $859,000 in 2024 and averaged $4.6 million.
  • Data for Autolus Therapeutics' Gains from Investment Securities shows a maximum YoY slumped of 96.45% (in 2024) over the last 5 years.
  • Over the past 4 years, Autolus Therapeutics' Gains from Investment Securities (Quarterly) stood at -$29.2 million in 2021, then reached $27.7 million in 2023, then tumbled by 96.45% to $751,000 in 2024, then decreased by 23.63% to $501,000 in 2025.
  • Its Gains from Investment Securities stands at $501,000 for Q3 2025, versus $967,000 for Q2 2025 and $71,000 for Q1 2025.